The biotechnology product company reported last month second-quarter earnings of $25.8 million, or 70 cents a share, down from year-earlier earnings of $26.5 million, or 72 cents."If industry conditions were to begin showing signs of firming or the stock were to pullback appreciably, we would consider revisiting our rating on this extremely well run business with an extraordinary financial model," Craig-Hallum analysts wrote in a Feb. 1 report. Forward Annual Dividend Yield: 1.7% Rated "B (Buy)" by TheStreet Ratings: The company's second-quarter gross profit margin decreased from the prior year. Techne is extremely liquid. Its Quick Ratio is 12.20, which shows it can meet its short-term cash needs. In the second quarter, stockholders' net worth increased 10.25% from the previous year. TheStreet Ratings' price target is $78.71. The stock closed Monday at $66.13. It has decreased 3.12% year to date. >>To see these stocks in action, visit the 10 Ex-Dividend Stocks With Buy Ratings portfolio on Stockpickr. -- Written by Alexandra Zendrian
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: email@example.com. >To follow the writer on Twitter, go to Alexandra Zendrian.